Triple-negative breast carcinoma

Related records

Broader conditions (20)

• Breast cancer
• Breast carcinoma
• Breast carcinoma by gene expression profile
• Breast disorder
• Breast neoplasm
• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Estrogen-receptor negative breast cancer
• Her2-receptor negative breast cancer
• Human disease
• Neoplasm
• Neoplasm of thorax
• Neoplastic disease or syndrome
• Progesterone-receptor negative breast cancer
• Thoracic cancer

Narrower conditions (1)

• Basal-like breast carcinoma

Trials (1,212)

• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
• [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
• 18F-FSPG PET/CT for Cancer Patients on Therapy
• 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
• 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• A Beta-only IL-2 ImmunoTherapY Study
• A Biomarker Screening Protocol for Participants With Solid Tumors
• A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
• A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
• A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
• A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
• A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
• A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
• A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Approved drugs (2)

• Atezolizumab
• Sacituzumab govitecan

Drugs in development (135)

• Adagloxad simolenin Phase 3
• Adavosertib Phase 1
• Alpelisib Phase 2
• Anastrozole Phase 2
• Avelumab Phase 2
• AZD-8186 Phase 1
• Bavituximab Phase 2
• Bemcentinib Phase 2
• Berzosertib Phase 1
• Bevacizumab Phase 2
• Bexarotene Phase 1
• Binimetinib Phase 2
• Bintrafusp alfa Phase 1
• Brostallicin Phase 2
• Bulumtatug fuvedotin Phase 1
• Camrelizumab Phase 3
• Capecitabine Phase 3
• Capivasertib Phase 2
• Carboplatin Phase 3
• Catequentinib Phase 2

Other linked drugs (2)

• Gilvetmab
• Sacituzumab